Porter Stuart D reported grant involving 25,000 shares of LIXTE BIOTECHNOLOGY HOLDINGS, INC. at $0.00 for $0 on May 29, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed Jun 1, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
25,000Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
25,000Direct
Trade date
May 29, 2026Grant
Filed
Jun 1, 2026, 4:01 PM ET3-day reporting delay
Accession
0001493152-26-026608Code A · Transaction 388626
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

LIXT price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LIXT · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −51%1w ago −18%1d ago −17%
Returns since7d −7.8%30d +6.4%90d 0%180d1y

Footnotes in full

F1: Represents a grant of 25,000 restricted share units ("RSUs"). The RSUs were granted pursuant to the Lixte Biotechnology Holdings, Inc. 2020 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon vesting, subject to continued service. The RSUs shall vest 25% on May 29, 2026, and 25% on the last date of each subsequent calendar quarter thereafter until fully vested.